Business Wire

ADDING and REPLACING CONVERT Clinical Trial Data Presented at ERS Demonstrates Early Success of AeriSeal System in Patients with Advanced COPD/Emphysema

REDWOOD CITY, Calif. & BARCELONA, Spain--(BUSINESS WIRE)--Please note the addition of citations at the end of the release dated Sept. 4, 2022. The updated release reads: CONVERT CLINICAL TRIAL DATA ...
Yahoo Finance

Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress ...

REDWOOD CITY, Calif. & VIENNA, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announced ...
Finanznachrichten

New Data from Two Multi-Center Randomized Clinical Trials Demonstrate That Zephyr Endobronchial Valves Deliver Benefit to Both Heterogeneous and Homogenous Emphysema Patients ...

Pulmonx®, Inc. today announced the results of two multi-center, randomized clinical trials showing clinically meaningful improvements in lung function after treatment with the Zephyr® Endobronchial ...
Business Wire

CONVERT Clinical Trial Data Presented at ERS Demonstrates Early Success of AeriSeal System in Patients with Advanced COPD/Emphysema

REDWOOD CITY, Calif. & BARCELONA, Spain--(BUSINESS WIRE)--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announces the ...
Financial Post

CONVERT Clinical Trial Data Presented at ERS Demonstrates Early Success of AeriSeal System in Patients with Advanced COPD/Emphysema

The reported data suggest that patients with collateral ventilation may be able to undergo successful treatment with Zephyr Endobronchial Valves following closure of collateral air channels with the ...